علاج سرطان قناة فالوب المتقدم (المرحلة الثالثة أو الرابعة وفق تصنيف FIGO) لدى النساء المؤهلات لإجراء جراحة إزالة الورم المثلى

References

DOI: 10.1200/JOP.18.00662

• National Comprehensive Cancer Network recommends that any woman with suspected epithelial ovarian cancer be evaluated by a gynecologic oncologist, because optimal surgical debulking by a skilled physician is central to the initial management of patients with advanced, stage III or IV disease.
• ASCO states that although primary cytoreductive surgery is preferred for patients with a high likelihood of achieving optimal debulking, women with high perioperative risk or a low likelihood of achieving optimal cytoreduction should receive neoadjuvant chemotherapy followed by possible interval surgery.
• To date, bevacizumab has been FDA approved for the following uses in epithelial ovarian cancer: in combination with carboplatin plus paclitaxel, followed by bevacizumab single agent for stage III or IV disease after initial surgical resection; in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent epithelial ovarian cancer after no more than two prior chemotherapy regimens; and in combination with carboplatin plus paclitaxel or carboplatin plus gemcitabine, followed by bevacizumab single agent, for platinum-sensitive recurrent epithelial ovarian cancer.
• Olaparib is approved as a treatment for patients with a germline BRCA mutation who have received at least three prior lines of chemotherapy.
• Rucaparib is similarly approved as a treatment after at least two prior lines of chemotherapy but in patients with a germline or a somatic BRCA mutation.